Pityriasis rosea after mRNA COVID‐19 vaccination

Abdullah, Lina; Hasbani, Divina Justina; Kurban, Mazen; Abbas, Ossama

doi:10.1111/ijd.15700

Cited by 31 publications

(50 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Atypical rashes reminiscent of pityriasis rosea following 4-7 days after mRNA vaccination have also been reported [6,7,19,20,25,26]. Unlike pityriasis rosea, these reactions are characterized by more itchy and diffuse lesions with a more frequent involvement of mucous membranes and no preceding herald patch [27]. It is still not clear whether pityriasis rosea-like exanthema is secondary to the direct invasion of SARS-CoV-2 or HHV-6/7 reactivation [27].…”

Section: Exanthemasmentioning

confidence: 99%

“…Unlike pityriasis rosea, these reactions are characterized by more itchy and diffuse lesions with a more frequent involvement of mucous membranes and no preceding herald patch [27]. It is still not clear whether pityriasis rosea-like exanthema is secondary to the direct invasion of SARS-CoV-2 or HHV-6/7 reactivation [27]. One case of figurate annular eruption following Ad26.CoV2.S vaccine was also reported [28].…”

Section: Exanthemasmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Bellinato

Maurelli

Gisondi

et al. 2021

JCM

View full text Add to dashboard Cite

Many patients are receiving SARS-CoV-2 vaccinations, which have been associated with a variety of adverse effects. Cutaneous adverse reactions to SARS-CoV-2 vaccinations have been progressively reported, but they have not been reviewed according to their morphological clinical patterns. The objective of this review was to summarize the existing data concerning the cutaneous adverse reactions following SARS-CoV-2 vaccines and group them according to common morphological and pathogenetic patterns. We reviewed the English language literature up to 15 August 2021, using predefined keywords to identify the relevant studies evaluating cutaneous adverse reactions associated with SARS-CoV-2 vaccines. We search for recurrent morphological patterns sharing clinical signs and symptoms and physio-pathological mechanisms. Timing to onset following the first or booster dose of the vaccine, predisposing conditions, therapeutic management, and outcome were also collected. Among the dermatological manifestations associated with SARS-CoV-2 vaccinations, we distinguished: (1) new onset reactions and (2) flares of preexisting dermatoses. The most common were injection site reactions, affecting 30–70% and generally mild or moderate. Small case series or single case reports included filler reactions, exanthemas, vascular lesions, urticaria, eczematous dermatitis, autoimmune bullous reactions, and severe cutaneous adverse reactions. In addition, the exacerbation of chronic immuno-mediated dermatoses (mainly psoriasis and atopic dermatitis) and reactivations of herpes infection were reported. The cutaneous reactions were generally mild, self-limiting, and resembled common cutaneous drug eruptions and/or COVID-19 skin manifestations.

show abstract

Section: Exanthemasmentioning

confidence: 99%

Section: Exanthemasmentioning

confidence: 99%

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Bellinato

Maurelli

Gisondi

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…The mechanisms behind these COVID-19-related symptoms remain unclear. Some studies have identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins on endothelial cells and lymphocytes from PR-like lesions, consistent with direct viral invasion (3,4). Moreover, COVID-19 may solely induce human herpesvirus reactivation through the immunomodulatory ability of SARS-CoV-2 to reactivate latent viruses (8,9).…”

Section: Discussionmentioning

confidence: 99%

“…The most commonly inoculated vaccines include those against smallpox, followed by tuberculosis, poliomyelitis, influenza, and human papillomavirus virus (12,13). Among patients who received COVID-19 vaccines, PR-like eruptions have been reported following the first (n = 1) or second dose (n = 2) of BNT162b2 mRNA-based vaccines (3,4). In some cases, central hyperpigmentation was identified.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination

2021

View full text Add to dashboard Cite

Vaccination is one of the cornerstones in the efforts towards ending the coronavirus disease 2019 (COVID-19) pandemic. However, several adverse effects of COVID-19 vaccination have been identified. Pityriasis rosea (PR)-like eruption is a rare cutaneous complication of immunization. To the best of our knowledge, there have been no reports of PR-like eruptions following inoculation with Oxford/AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine. Here, we described a case of PR-like eruption that developed 14 days after Oxford/AstraZeneca vaccination in a 52-year-old Thai woman with glioblastoma. Treatment with topical 0.1% triamcinolone acetonide twice per day showed partial response after seven days. Despite this rare complication, our report highlights that the presence of PR-like eruption is not a contraindication for subsequent vaccinations.

show abstract

“… 16 , 23 , 24 Although the diagnosis of PR has become more common during the COVID‐19 pandemic, it is still unclear whether this cutaneous manifestation is secondary to the direct invasion of SARS‐CoV‐2, because in PR lesions the virus protein was found, whether it is due to reactivation of latent viruses such as HHV‐6/7 and HHV‐4 or EBV (Epstein–Barr virus) by the immunomodulatory capacity of COVID‐19 to reactivates them or whether due to other factors. 16 Among the other factors is PR as a secondary reaction after vaccine protocols 25 , 26 , 27 , 28 , 29 , 30 , 31 being an important alert to dermatologists and other professionals in the area to assist in diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Pityriasis rosea‐like cutaneous eruption as a possible dermatological manifestation after Oxford‐AstraZeneca vaccine: Case report and brief literature review

Pedrazini

Silva²

2021

Dermatologic Therapy

View full text Add to dashboard Cite

Pityriasis rosea (PR) has been manifested in patients suffering from COVID‐19 as well as after vaccine protocols against SARS‐CoV‐2. It has a possible association with the HHV‐6B virus ( roseola infantum ) and can be controlled by antivirals such as acyclovir as well as by the amino acid l ‐Lysine that showed a positive result in reducing the number of lesions and healing time. The aim of this study was to report a case of PR after a second dose of Oxford‐AstraZeneca, the adopted therapy and a brief literature review. A 53‐year‐old woman, phototype II, presented an erythematous lesion in the posterior right thigh 15 days after the second dose of Oxford‐AstraZeneca vaccine. Eight days after the initial injury, new injuries appeared in the calf, buttocks and thighs. The diagnosis was PR with a 5‐week eruption cycle. The treatment consisted of the use of l ‐Lysine, 3 grams loading dose and 500 mg for 30 days and moisturizing/healing lotion, starting 14 days after the herald patch. After the 5th week of the disease cycle, there were no new eruptions and the repair cycle continued for up to 8 weeks leaving some residual skin spots. It is concluded that the patient may be a carrier a latent virus, HHV‐6, and the vaccine administration with immune system stimulation, would have activated the possible virus causing PR. l ‐Lysine helped to control the manifestation by limiting the number of lesions and their location, which were restricted to the legs, thighs and buttocks.

show abstract

Pityriasis rosea after mRNA COVID‐19 vaccination

Cited by 31 publications

References 6 publications

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination

Pityriasis rosea‐like cutaneous eruption as a possible dermatological manifestation after Oxford‐AstraZeneca vaccine: Case report and brief literature review

Contact Info

Product

Resources

About